Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL

Thomas J. Kipps, MD, PhD
Published: Tuesday, Dec 08, 2015



Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Ibrutinib is a first-in-class, oral, Bruton's tyrosine kinase inhibitor that is FDA approved for patients with CLL who received more than one prior therapy, as well as for patients with del17p.

The phase III randomized study evaluated ibrutinib in treatment-naïve patients 60 to 65 years old who did not have the 17p deletion. Both regimens were found to be well tolerated. However, patients who received ibrutinib had higher progression-free survival, overall survival, overall response rate, event-free survival, and hematologic improvement versus those who received chlorambucil. There was also an 84% reduction in the risk of death in the ibrutinib arm.

<<< View more from the 2015 ASH Annual Meeting



Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Ibrutinib is a first-in-class, oral, Bruton's tyrosine kinase inhibitor that is FDA approved for patients with CLL who received more than one prior therapy, as well as for patients with del17p.

The phase III randomized study evaluated ibrutinib in treatment-naïve patients 60 to 65 years old who did not have the 17p deletion. Both regimens were found to be well tolerated. However, patients who received ibrutinib had higher progression-free survival, overall survival, overall response rate, event-free survival, and hematologic improvement versus those who received chlorambucil. There was also an 84% reduction in the risk of death in the ibrutinib arm.

<<< View more from the 2015 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x